Efficacy and tolerability of an herbal formulation for weight management

Journal of Medicinal Food

Volumn 16, Issue 6, 2013, Pages 529-537

  Stern, Judith S ^a,b   Peerson, Jan ^a   Mishra, Artatrana T ^c   Mathukumalli, Venkata Sadasiva Rao ^d   Konda, Poorna Rajeswari ^e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Department of Radiodiagnosis   (India)

^d Alluri Sitaramaraju Academy of Medical Sciences   (India)

^e Suraksha Health Village   (India)

Author keywords

Adiponectin; Clinical study; Garcinia mangostana; Sphaeranthus indicus; Weight loss

Indexed keywords

ADIPONECTIN; CHOLESTEROL; GARCINIA MANGOSTANA EXTRACT; GLUCOSE; HERBACEOUS AGENT; MERATRIM; PLACEBO; PLANT EXTRACT; SPHAERANTHUS INDICUS EXTRACT; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANKLE PAIN; ARTHRALGIA; ARTICLE; BACKACHE; BODY MASS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FORMULATION; DRUG MIXTURE; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAM; FLOWER HEAD; GARCINIA MANGOSTANA; GASTROINTESTINAL IRRITATION; GLUCOSE BLOOD LEVEL; HEADACHE; HIP CIRCUMFERENCE; HUMAN; LEG PAIN; LIPID BLOOD LEVEL; NAUSEA; OBESITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SPHAERANTHUS INDICUS; TREATMENT OUTCOME; VITAL SIGN; WEIGHT REDUCTION;

ADIPONECTIN; ADULT; ANTI-OBESITY AGENTS; ASTERACEAE; BLOOD GLUCOSE; BODY MASS INDEX; BODY WEIGHT; FEMALE; GARCINIA MANGOSTANA; HUMANS; MALE; OBESITY; PHYTOTHERAPY; PLANT EXTRACTS; TREATMENT OUTCOME; TRIGLYCERIDES; WAIST CIRCUMFERENCE; WEIGHT LOSS;

GARCINIA MANGOSTANA; SPHAERANTHUS INDICUS;

EID: 84879426222     PISSN: 1096620X     EISSN: 15577600     Source Type: Journal    
DOI: 10.1089/jmf.2012.0178     Document Type: Article

References (37)

1. WHO: Obesity and Overweight. Fact sheet No. 311. www.who .int/mediacentre/factsheets/fs311/en/index.html (accessed November 2012).
2. Faust IM, Johnson PR, Stern JS, et al.: Diet-induced adipocyte number increase in adult rats: A new model of obesity. Am J Physiol 1978;235:E279-E286
3. Klyde BJ, Hirsch J: Increased cellular proliferation in adipose tissue of adult rats fed a high-fat diet. J Lipid Res 1979;20: 705-715
4. Klyde BJ, Hirsch J: Isotopic labeling of DNA in rat adipose tissue: Evidence for proliferating cells associated with mature adipocytes. J Lipid Res 1979;20:691-704
5. Mallare JT, Karabell AH, Velasquez-Mieyer P, et al.: Current and future treatment of metabolic syndrome and type 2 diabetes in children and adolescents. Diabetes Spectrum 2005;18:220-228
6. Schnee DM, Zaiken K, McCloskey WW: An update on the pharmacological treatment of obesity. Curr Med Res Opin 2006; 22:1463-1474
7. Bray GA, Ryan DH: Drug treatment of the overweight patient. Gastroenterology 2007;132:2239-2252
8. Kang JG, Park CY: Anti-obesity drugs: A review about their effects and safety. Diabetes Metab J 2012;36:13-25
9. Hubbard VS, Hall WH: Gastrointestinal Surgery for Severe Obesity. Obes Surg 1991;1:257-265
10. Pittler MH, Ernst E: Dietary supplements for body-weight reduction: A systematic review. Am J Clin Nutr 2004;79:529-536
11. Pillitteri JL, Shiffman S, Rohay JM, et al.: Use of dietary supplements for weight loss in the United States: Results of a national survey. Obesity (Silver Spring) 2008;16:790-796
12. Kolotkin RL, Head S, Hamilton M, et al.: Assessing impact of weight on quality of life. Obes Res 1995;3:49-56
13. Kolotkin RL, Crosby RD, Kosloski KD, et al.: Development of a brief measure to assess quality of life in obesity. Obes Res 2001; 9:102-111
14. ADAM, Inc.: Medical encyclopedia: MedlinePlus. www.nlm .nih.gov/medlineplus.gov/medlineplus/encyclopedia.html (accessed November 2012).
15. Mayo Foundation for Medical Education and Research: Mayo Clinic. www.mayoclinic.com (accessed November 2012).
16. Guebre-Egziabher F, Bernhard J, Funahashi T, et al.: Adiponectin in chronic kidney disease is related more to metabolic disturbances than to decline in renal function. Nephrol Dial Transplant 2005;20:129-134
17. Kern PA, Di Gregorio GB, Lu T, et al.: Adiponectin expression from human adipose tissue: Relation to obesity, insulin resistance, and tumor necrosis factor-alpha expression. Diabetes 2003;52: 1779-1785
18. Elsayed EF, Tighiouart H, Weiner DE, et al.: Waist-to-hip ratio and body mass index as risk factors for cardiovascular events in CKD. Am J Kidney Dis 2008;52:49-57
19. Taylor RW, Keil D, Gold EJ, et al.: Body mass index, waist girth, and waist-to-hip ratio as indexes of total and regional adiposity in women: Evaluation using receiver operating characteristic curves. Am J Clin Nutr 1998;67:44-49
20. Janssen I, Katzmarzyk PT, Ross R: Waist circumference and not body mass index explains obesity-related health risk. Am J Clin Nutr 2004;79:379-384
21. Fox CS, Massaro JM, Hoffmann U, et al.: Abdominal visceral and subcutaneous adipose tissue compartments: Association with metabolic risk factors in the Framingham Heart Study. Circulation 2007;116:39-48
22. Stern JS, Hirsch J, Blair SN, et al.: Weighing the options: Criteria for evaluating weight-management programs. The Committee to Develop Criteria for Evaluating the Outcomes of Approaches to Prevent and Treat Obesity. Obes Res 1995;3: 591-604
23. Brun RP, Spiegelman BM: PPAR gamma and the molecular control of adipogenesis. J Endocrinol 1997;155:217-218
24. Yamauchi T, Waki H, Kamon J, et al.: Inhibition of RXR and PPARgamma ameliorates diet-induced obesity and type 2 diabetes. J Clin Invest 2001;108:1001-1013
25. Jones JR, Barrick C, Kim KA, et al.: Deletion of PPARgamma in adipose tissues of mice protects against high fat diet-induced obesity and insulin resistance. Proc Natl Acad Sci U S A 2005; 102:6207-6212
26. Bonen A, Tandon NN, Glatz JF, et al.: The fatty acid transporter FAT/CD36 is upregulated in subcutaneous and visceral adipose tissues in human obesity and type 2 diabetes. Int J Obes (Lond) ;30:877-883
27. Faleck DM, Ali K, Roat R, et al.: Adipose differentiation-related protein regulates lipids and insulin in pancreatic islets. Am J Physiol Endocrinol Metab 2010;299:E249-E257
28. Tansey JT, Sztalryd C, Gruia-Gray J, et al.: Perilipin ablation results in a lean mouse with aberrant adipocyte lipolysis, enhanced leptin production, and resistance to diet-induced obesity. Proc Natl Acad Sci U S A 2001;98:6494-6499
29. Yamauchi T, Kamon J, Minokoshi Y, et al.: Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002;8:1288- 1295
30. Yamauchi T, Kamon J, Waki H, et al.: The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001;7:941-946
31. Wang H, Peng DQ: New insights into the mechanism of low high-density lipoprotein cholesterol in obesity. Lipids Health Dis 2011;10:176
32. Martyn JA, Kaneki M, Yasuhara S: Obesity-induced insulin resistance and hyperglycemia: Etiologic factors and molecular mechanisms. Anesthesiology 2008;109:137-148
33. Stefan N, Vozarova B, Funahashi T, et al.: Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans. Diabetes 2002;51:1884-1888
34. Riazi A, Shakoor S, Dundas I, et al.: Health-related quality of life in a clinical sample of obese children and adolescents. Health Qual Life Outcomes 2010;8:134
35. Swallen KC, Reither EN, Haas SA, et al.: Overweight, obesity, and health-related quality of life among adolescents: The National Longitudinal Study of Adolescent Health. Pediatrics 2005;115: 340-347
36. Kawachi I: Physical and psychological consequences of weight gain. J Clin Psychiatry 1999;60 Suppl 21:5-9
37. Loux TJ, Haricharan RN, Clements RH, et al.: Health-related quality of life before and after bariatric surgery in adolescents. J Pediatr Surg 2008;43:1275-1279